Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 2 Published - 14:00 UTC    08:00 EST    11-January-2001      
Issue 11 Next Update - 14:00 UTC 08:00 EST    12-January-2001      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya




















Back To Vidyya FDA Approves Femara

As First-Line Therapy For Advanced Breast Cancer


The FDA today approved a new indication for the breast cancer drug, Femara (letrozole) as a first-line treatment for postmenopausal women with hormone receptor positive or hormone receptor unknown, advanced or metastatic breast cancer. Femara, an aromatase inhibitor, was approved for treatment of advanced breast cancer in 1997 in women whose cancer had not responded to antiestrogen drugs.

Femara was shown to be more effective than tamoxifen in a randomized, double-blinded, multinational trial of more than 900 postmenopausal women, with locally advanced or metastatic breast cancer not amenable to treatment with surgery or radiation. In the study, Femara was found superior to tamoxifen in delaying time to progression of disease. Median time to disease progression with Femara was 9.4 months compared to 6 months for tamoxifen.

The incidence of side effects in the study was similar for Femara and tamoxifen with the most frequently reported side effects including bone pain, hot flushes, back pain nausea, arthralgia (or joint pain) and dyspnea (or labored breathing).

On December 13, FDAs Oncology Drugs Advisory committee unanimously recommended approval of Femara for initial hormone treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown advanced metastatic breast cancer. The drug is manufactured by Novartis Pharmaceuticals Corp., East Hanover, New Jersey.

Vidyya has the full prescribing information for Femara. Search keywork "Femara" on our search page.


Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.